These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 1365458)

  • 1. Alan Horn Memorial Lecture. Selective probes for characterization of dopamine D1 and D2 receptors.
    Neumeyer JL; Baindur N; Bakthavachalam V; Yuan J; Madras BK; Kula NS; Campbell A; Baldessarini RJ
    Neurochem Int; 1992 Mar; 20 Suppl():63S-68S. PubMed ID: 1365458
    [No Abstract]   [Full Text] [Related]  

  • 2. Characterization of novel fluorescent ligands with high affinity for D1 and D2 dopaminergic receptors.
    Monsma FJ; Barton AC; Kang HC; Brassard DL; Haugland RP; Sibley DR
    J Neurochem; 1989 May; 52(5):1641-4. PubMed ID: 2523470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorescent and biotin probes for dopamine receptors: D1 and D2 receptor affinity and selectivity.
    Madras BK; Canfield DR; Pfaelzer C; Vittimberga FJ; Difiglia M; Aronin N; Bakthavachalam V; Baindur N; Neumeyer JL
    Mol Pharmacol; 1990 Jun; 37(6):833-9. PubMed ID: 2141665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple fluorescent ligands for dopamine receptors. I. Pharmacological characterization and receptor selectivity.
    Barton AC; Kang HC; Rinaudo MS; Monsma FJ; Stewart-Fram RM; Macinko JA; Haugland RP; Ariano MA; Sibley DR
    Brain Res; 1991 May; 547(2):199-207. PubMed ID: 1679366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A D1/D2 chimeric dopamine receptor mediates a D1 response to a D2-selective agonist.
    MacKenzie RG; Steffey ME; Manelli AM; Pollock NJ; Frail DE
    FEBS Lett; 1993 May; 323(1-2):59-62. PubMed ID: 8098694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular electrostatic potential of D1 and D2 dopamine agonists.
    Alkorta I; Villar HO
    J Med Chem; 1994 Jan; 37(1):210-3. PubMed ID: 7904647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zinc allosterically modulates antagonist binding to cloned D1 and D2 dopamine receptors.
    Schetz JA; Sibley DR
    J Neurochem; 1997 May; 68(5):1990-7. PubMed ID: 9109525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Localization of dopaminergic markers in the human subthalamic nucleus.
    Augood SJ; Hollingsworth ZR; Standaert DG; Emson PC; Penney JB
    J Comp Neurol; 2000 May; 421(2):247-55. PubMed ID: 10813785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
    Hu XT; White FJ
    Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characterization of dopamine receptors.
    Bates MD; Gingrich JA; Bunzow JR; Falardeau P; Dearry A; Senogles SE; Civelli O; Caron MG
    Am J Hypertens; 1990 Jun; 3(6 Pt 2):29S-33S. PubMed ID: 2143386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the binding of SCH 39166 to the five cloned dopamine receptor subtypes.
    Tice MA; Hashemi T; Taylor LA; Duffy RA; McQuade RD
    Pharmacol Biochem Behav; 1994 Nov; 49(3):567-71. PubMed ID: 7862709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine induces inhibitory effects on the circular muscle contractility of mouse distal colon via D1- and D2-like receptors.
    Auteri M; Zizzo MG; Amato A; Serio R
    J Physiol Biochem; 2016 Aug; 73(3):395-404. PubMed ID: 28600746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions between D1 and D2 dopamine receptor family agonists and antagonists: the effects of chronic exposure on behavior and receptor binding in rats and their clinical implications.
    Braun AR; Laruelle M; Mouradian MM
    J Neural Transm (Vienna); 1997; 104(4-5):341-62. PubMed ID: 9295170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Further evidence for the mediation of both subtypes of dopamine D1/D2 receptors and cerebral neuropeptide Y (NPY) in amphetamine-induced appetite suppression.
    Kuo DY
    Behav Brain Res; 2003 Dec; 147(1-2):149-55. PubMed ID: 14659580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction between dopamine D1 and D2 receptors in modulation of the immune response.
    Devoino LV; Al'perina EL; Gevorgyan MM; Cheido MA
    Bull Exp Biol Med; 2006 May; 141(5):553-5. PubMed ID: 17181050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative structure activity relationships (QSAR) of substituded (S)-phenylpiperidines as preferential dopamine autoreceptor antagonists.
    Pontiki EA; Hadjipavlou-Litina DJ; Demertzis AM; Hadjidakis I; Kovala-Demertzi D
    J Enzyme Inhib Med Chem; 2005 Feb; 20(1):5-12. PubMed ID: 15895678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic dopamine D1, dopamine D2 and combined dopamine D1 and D2 antagonist treatment in Cebus apella monkeys: antiamphetamine effects and extrapyramidal side effects.
    Peacock L; Hansen L; Mørkeberg F; Gerlach J
    Neuropsychopharmacology; 1999 Jan; 20(1):35-43. PubMed ID: 9885783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biotin ergopeptide probes for dopamine receptors.
    Vendrell M; Molero A; González S; Pérez-Capote K; Lluis C; McCormick PJ; Franco R; Cortés A; Casadó V; Albericio F; Royo M
    J Med Chem; 2011 Feb; 54(4):1080-90. PubMed ID: 21280602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of drug-induced catalepsy based on dopamine D1, D2, and muscarinic acetylcholine receptor occupancies.
    Haraguchi K; Ito K; Kotaki H; Sawada Y; Iga T
    Drug Metab Dispos; 1997 Jun; 25(6):675-84. PubMed ID: 9193868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional interaction between dopamine D1 and D2 receptors in 'MPTP' monkeys.
    Luquin MR; Guillén J; Martínez-Vila E; Laguna J; Martínez-Lage JM
    Eur J Pharmacol; 1994 Mar; 253(3):215-24. PubMed ID: 7911084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.